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Background: The adherence to treatment with injectable disease-modifying drugs (DMDs) 
in multiple sclerosis (MS) may benefit from adequate information provision and management 
of expectations. The communication between patients and physicians is very important in this 
respect. The current study investigated the perspectives and experiences of the MS patients and 
neurologists concerning the choice and course of treatment with DMDs in the Netherlands.
Methods: The MS patients (aged 18–60 years; diagnosed with MS at least a year ago, 
currently treated with injectable DMD treatment) and MS-specialized neurologists (practicing 
for 3 years, treating 15 MS patients/month on average, and spending 60% of their time 
in clinical practice) were asked to complete semistructured Internet-based questionnaires. The 
neurologists in this study were not necessarily the treating neurologists of the participating 
MS patients.
Results: In all, 107 MS patients and 18 MS-specialized neurologists completed the question-
naires. The MS-specialized neurologists in this study reported discussing most of the suggested 
treatment goals with their patients. The MS patients indicated that certain important treatment 
goals, ie, reduction in disease progression, reduction or prolongation of time to long-term dis-
ability, and reduction in new magnetic resonance imaging lesions, were not discussed with them. 
More than one-quarter of the patients (27%) would appreciate more information about their 
treatment. We found evidence for suboptimal patient adherence to MS therapy (23% indicated 
taking a treatment break) due to diverse side effects, lack of efficacy, or practical issues. As 
compared to these patient reports, the scale of poor adherence was overestimated by more than 
half of the neurologists (on average, 30% estimated treatment breaks).
Conclusion: The MS patients and MS-specialized neurologists in this study differ in their 
experiences and perspectives on information provision and adherence to DMDs. Education 
programs and up-to-date information on MS treatments for both neurologists and patients may 
be helpful in improving patient involvement and patient–physician communication.
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Introduction
Several injectable disease-modifying drugs (DMDs) are available for the treatment 
of multiple sclerosis (MS) aimed at decreasing the frequency and severity of relapses 
and limiting disease progression. These drugs are often prescribed in an early stage 
of the disease. Many studies demonstrate poor adherence to long-term therapy.1–3 
The World Health Organization defines adherence as “the extent to which a person’s 
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behaviour – taking medication, following a diet, and/or 
executing lifestyle changes, corresponds with agreed rec-
ommendations from a health care provider”.4 In the MS 
patients, treatment adherence to DMDs varies between 
52% and 63%.1–3 The reasons to discontinue treatment are a 
perceived lack of treatment effect, side effects, fatigue, and 
depression.5,6 Treatment adherence may benefit by offering 
people with MS better information about the effects of the 
treatment and more involvement in the choice of treatment. 
A recent study suggests that the perspectives of patients and 
physicians concerning the choice and course of treatment 
with DMDs may differ significantly.7 Patient adherence to 
treatment was overestimated by the physicians.7 One in five 
MS patients reported that the different treatment options were 
not discussed with them prior to the selection of a DMD by 
their medical team.6
In order to improve information about the available treat-
ment options and improve communication between a patient 
and a physician, it is important to compare the experiences 
and perspectives on treatment of both groups. As an addi-
tion to the study of Riñon et al,7 the current study focuses 
on the Dutch situation. We also made an inventory of the 
patients’ and neurologists’ preferred methods to gather or 
share information about treatment goals. We have the fol-
lowing research questions:
•	 What are the patient perspectives and experiences on 
DMD treatment initiation and continuation?
•	 What are the neurologist perspectives and experiences on 
DMD treatment initiation and continuation, and to what 
extent are these similar to the patient perspectives and 
experiences?
Methods
recruitment of respondents
Patients affiliated with the National Multiple Sclerosis 
Foundation were directly invited to participate in the 
Dutch MS Choices Survey through invitation by email. 
Advertisements were placed in the quarterly newsletter 
“MS Nieuwslijn” and on the websites of the National Multiple 
Sclerosis Foundation (www.nationaalmsfonds.nl and www.
msyoung.nl). Patients participating in the web-based Dutch 
Multiple Sclerosis Study, a prospective long-term assessment 
of health-related quality of life and disabilities in MS, were 
informed via email. The study information and the consent 
form were available and could be downloaded from the 
website. The information given to the potential participants 
concerned the purpose of the study, the eligibility criteria, 
the kind of data to be obtained, where the data were to be 
stored, and who was the principal investigator. No incentives 
were offered.
Neurologists were included based on the following 
criteria: practicing as a neurologist for 3 years, treating at 
least 15 MS patients/month on average, and spending 60% 
of their time in clinical practice. Based on these criteria, 
we decided to invite all MS-specialized neurologists from 
the Dutch Society of MS Neurologists (N=33). They were 
approached by Leo H Visser and asked to participate in this 
study. Twenty-two neurologists were willing to participate, 
and finally, 18 neurologists completed the questionnaires.
Inclusion criteria for patients included being diagnosed 
with MS at least a year ago, aged between 18 years and 
60 years, and currently being treated with an injectable 
DMD. Patients included in this study were not necessarily 
treated by the neurologists. It should be noted that Dutch 
MS patients can choose to be treated by any neurologist, and 
thereby have access to an MS-specialized neurologist. The 
study was approved by the Medical Ethical Committee of 
the St Elisabeth Hospital in Tilburg. All respondents gave 
informed consent by means of a checkbox online.
Data collection
The survey consisted of one questionnaire for patients (see the 
Supplementary materials) and one for neurologists (see the 
Supplementary materials). They were based on the question-
naires designed by Riñon et al7 who conducted a similar survey 
in seven countries, ie, Australia, Canada, France, Germany, 
Italy, Spain, and the UK. The questionnaires inquired about the 
type of treatment, treatment initiation, supply, factors involved 
in the choice of treatment, treatment goals, sources of informa-
tion used and needed, side effects, adherence (measured by 
inquiring about treatment interruptions and discontinuations), 
opinions about newly available oral treatments, and what fac-
tors are important for treatment continuation.
The data were collected between July 2014 and June 
2015. Patients completed a semistructured Internet-based 
questionnaire that took ~20 minutes to complete. The study 
was performed using the LimeSurvey software, an open-
source online application operative on the MS4 Research 
Institute’s platform. The items of the questionnaire were 
fixed. The responses were automatically captured. To pro-
tect the personal data from unauthorized access, various 
mechanisms were used to comply with the European Union 
regulations concerning online medical data, including the 
use of a personal username and a strong password, separa-
tion of answers from questions in the database of personal 
information, each screen having a username and password 
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protection, virtual private network tunneling, 256-bit encryp-
tion, and the encryption of the participants’ identities via 
unique 15-digit codes. Automated checks on completeness 
were done before questionnaires could be submitted. The 
respondents saw an overview of all questions and answers 
before submission, and they could change the answers before 
submitting. After submission, changes were no longer pos-
sible. Only completed questionnaires were analyzed. The help 
desk (MAH) contacted respondents by phone in case they did 
not succeed in completing questionnaires. No methods were 
used to adjust for a nonrepresentativeness of the sample.
The questionnaire consisted of 47 closed-ended questions 
(each with two to ten possible answers) and two open-ended 
questions. In a question concerning factors involved in decid-
ing what treatment to take, the importance of a given factor 
was questioned on a scale from 1 (not important at all) to 
5 (extremely important). The Internet-based questionnaire for 
neurologists took ~15 minutes to complete. This question-
naire consisted of 27 closed-ended questions (each with two 
to nine possible answers) and seven open-ended questions, 
mostly concerning an estimate on the percentage of patients 
involved.
When clicking the hyperlink needed to start the online 
questionnaire, the inclusion criteria were first checked using 
several closed-ended questions. When the patient met all 
the inclusion criteria, an informed consent was presented. 
If informed consent was given, the link to the questionnaire 
was provided by email.
Results
Demographics
In all, 107 MS patients and 18 MS-specialized neurologists 
completed the questionnaire.
Treatment decisions and initiation
Patient involvement
Most of the neurologists (83%; 15/18) believe that patients 
should select their treatment after discussing the options 
with their physician. In all, 72% of the neurologists (13/18) 
stated that their patients were fully involved in the decision 
process. The other 28% (five of 18) stated that their patients 
were fairly involved.
Overall, 59% of the patients (63/107) stated that they were 
responsible for the selection of their treatment after discuss-
ing the treatment options with their medical team. In 27% of 
the patients (29/107), treatment options were discussed and 
a treatment was recommended by their physician. A total of 
14% of the patients (15/107) reported that their treatment was 
selected for them without any discussion of the options.
Time to treatment initiation
Most neurologists, ie, 78% (14/18), initiated treatment within 
6 months after diagnosis and the remainder within 12 months. 
Most patients, ie, 62% (66/107), reported initiating treatment 
within 6 months after diagnosis. Almost one-quarter of the 
patients (24%; 26/107) initiated treatment 12 months after 
being diagnosed with MS.
Factors important for treatment choice
Factors that are considered important by patients for deciding 
what treatment to take are listed in Table 1. The effectiveness 
of the treatment for reducing relapses and effectiveness of 
the treatment for reducing disease progression are selected 
by, respectively, 51% and 54% of the patients and are both 
considered highly important; mean (SD): 4.5 (0.9). Treat-
ment frequency (selected by 41%) and possible side effects 
of the treatment (selected by 40%) are selected as third and 
Table 1 Factors in deciding what treatment to take (patient report)
Factors for treatment choice Percentage of patients who 
believed the factor to be important
Importance, 
mean (SD)
how effective the treatment would be in reducing 
relapses
51 4.5 (0.9)
how effective the treatment would be in reducing 
disease progression
54 4.5 (0.9)
Possible side effects from taking the treatment 40 3.6 (1.1)
how the treatment would be taken 30 3.0 (1.4)
how frequently the treatment would be taken 41 3.3 (1.5)
how it could affect your quality of life 29 4.2 (0.9)
Long-term safety profile of the treatment 22 3.9 (1.2)
Availability of a patient program (offering 
instructions for administration)
4 3.0 (1.3)
Other factor 13 1.9 (1.4)
Notes: importance is scored on a scale from 1 (not important at all) to 5 (extremely important). Mean (sD) is noted. Patient-rated importance scores all varied between 1 and 5.
Abbreviation: sD, standard deviation.
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fourth important factors, respectively. How the treatment 
affects the quality of life and the long-term safety profile 
are selected by a lower percentage of patients, but are rated 
highly important. Other factors mentioned by the patients 
included “how to preserve the medication during travel” and 
“effects on fatigue”.
Table 2 lists which treatment goals are being discussed 
according to both patients and neurologists. The neurologists 
discuss most of the suggested treatment goals with their 
patients. However, a much lower number of patients indicate 
that these treatment goals have been discussed with them, 
especially concerning the reduction in disease progression, 
the reduction or prolongation of time to long-term disability, 
and the reduction in new magnetic resonance imaging lesions. 
In all, 27% of the patients would like to have more informa-
tion about their treatment, via either the neurologist (21%), 
the MS nurse (15%), a patient organization (6%), a brochure 
(12%) or a website with accurate information (13%).
Most neurologists, ie, 56% (ten of 18), would appreci-
ate materials to discuss treatment goals with their patients, 
eg, brochures (30%), websites with accurate information 
(50%), medication choice models (10%), or expert panel 
summaries of the literature (11%).
Treatment continuation
Adherence
On average, neurologists estimated that 30% (ranging from 
5% to 80%) of the MS patients who they treated have taken 
a break from treatment and that 16% discontinued treatment 
(ranging from 2% to 40%). In all, 23% of the MS patients 
reported taking a treatment break for 1 day and 19% 
reported that they stopped taking their treatment. Almost 
all neurologists (17/18) felt that adherence is an issue when 
treating the MS patients. As the most important factor to 
improve adherence, 33% of the neurologists (six of 18) 
selected “if their medication improves overall well-being”, 
followed by “no more injections” (22%; four of 18) and “tak-
ing treatment less frequently” (17%; three of 18).
reasons for taking a break or stopping treatment
The neurologists most frequently noted “side effects (in 
general)” as the main reason why the MS patients may 
take a break or stop treatment (94% of the neurologists), 
followed by “disease showing no signs of decline” (56% of 
the neurologists; Figure 1). According to the neurologists, 
injection-site reactions (50%) and flu-like symptoms (56%) 
are the two side effects with the greatest impact on treatment 
adherence, followed by mood changes (33%). When asked 
whether psychological or physical factors or both led to the 
decision to take a break or stop the treatment, neurologists 
viewed either a combination of physical and psychological 
factors (33%), physical factors alone (33%), or psychological 
factors alone (33%) as most likely.
The majority of patients who reported having taken a 
break or stopping treatment considered physical factors 
(74%) the main reason. Only 32% of the patients who 
reported having taken a break or stopping treatment men-
tioned “side effects of the treatment” as the main reason 
for doing so, followed by “the treatment was not working” 
(12%), and “practical issues from taking the treatment” 
(12%). The side effects that made them decide to take a break 
or stop treatment were diverse: flu-like symptoms (three of 
eleven), tiredness/lethargy (one of eleven), mood changes 
(one of eleven), bowel problems (one of eleven), blindness 
in one eye (one of eleven), macula edema (one of eleven), 
and progressive multifocal leukoencephalopathy (due to 
Table 2 Treatment goals discussed according to patients and neurologists
Treatment goals Percentage of patients (N=107) 
indicating that the treatment goal 
was sufficiently discussed with them
Percentage of neurologists (N=18) 
indicating that they discussed the 
treatment goal with their patients
longer between/less frequency 
of attacks/episodes/flare-ups
76 89
Decrease in severity of attacks/episodes/
flare-ups
72 83
reduction in disease progression 69 94
Maintains current status/condition 76 72
Prevents symptoms getting worse  
(eg, cognition, fatigue)
65 61
long-term disability is reduced/prolongs 
time to long-term disability
55 94
reduction in new Mri lesions 54 94
less reduction in total brain volume 23 11
improvement in quality of life 57 50
Abbreviation: Mri, magnetic resonance imaging.
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previous Tysabri use; one of eleven). Two of eleven patients 
did not know the reason.
side effects in general
In all, 80% of the patients reported experiencing side effects 
from the MS treatment at some point during their treatment. 
In 50%, these side effects have affected their daily life. 
Flu-like symptoms (selected by 36%), tiredness/lethargy 
(selected by 28%), and injection-site reactions (selected by 
24%) affected daily life the most.
information sources
Most patients indicated using the neurologist (73%), the MS 
nurse (63%), or the nurse from their patient support program 
(42%) as a source to get more information on how to man-
age their MS treatment more effectively (Figure 2). Other 
sources included online sources or websites (used by 57% of 
the patients), the MS society or association (used by 27%), 
and the manufacturer’s website (22%).
new treatment/innovation
On the question “Which new treatment/innovation do you 
believe would be likely to benefit you most, as an MS 
patient, if it was available?”, most patients answered “oral 
therapy” (34%) or “do not know” (34%). In those who 
answered “oral therapy”, the majority (78%) explained that 
this is because they would not have to take injections any 
more. Of all patients, 89% would still make the choice of 
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injectable medication if oral medication was going to be 
less effective (Figure 3).
On the question “Which treatment/management 
interventions do you believe would be likely to benefit MS 
patients the most if they were available?”, most neurologists 
(39%; seven of 18) answered “new specific biological 
therapies”, followed by an “other” type of treatment, ie, “a 
treatment with effect on disease progression” given by 22% 
(four of 18) of the neurologists (Figure 4).
Discussion
This study was aimed at examining patient and neurologist 
perspectives and experiences concerning treatment initiation 
and continuation of injectable DMDs. In the study by Riñon 
et al,7 a substantial disparity was found between the views of 
patients and neurologists concerning treatment with injectable 
DMDs, although there were many differences between the 
countries involved (ie, Australia, Canada, France, Germany, 
Italy, Spain, and the UK). DMD benefits are generally con-
sidered the greatest when the treatment is started early in the 
disease course.8 In accordance with the timing of treatment 
initiation in Spain (82%), 78% of the MS-specialized neurolo-
gists in the Netherlands initiated treatment within 6 months 
after diagnosis. Patient experiences were fairly similar to the 
neurologists’ perspective; 62% reported initiating treatment 
within 6 months after diagnosis. However, although none 
of the neurologists in our study initiated treatment after 
12 months, 24% of the patients indicated starting treatment 
12 months after being diagnosed with MS. It is unclear why 
patient and neurologist perspectives differ in this respect, but 
this discrepancy was also found in the study by Riñon et al. 
One hypothesis is that these patients decided themselves to 
start treatment at a later time. Another hypothesis concerns 
differences between general and MS-specialized neurolo-
gists. The neurologists in this study were not necessarily the 
treating neurologists of the MS patients who participated in 
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the study. Immunomodulating therapies in the Netherlands 
can be prescribed by general neurologists as well as MS-
specialized neurologists. The questionnaire was filled in 
by patients who were treated by either an MS-specialized 
neurologist or a general neurologist. As only MS-specialized 
neurologists participated in this study, it is possible that these 
neurologists advised patients to start treatment earlier than 
the general neurologists.
Most neurologists (83%) in the current study believed 
that patients should select their treatment after discussing the 
options with their medical team. In the study by Riñon et al, 
only 58% shared this belief. None of the neurologists in the 
current study believed that patients should not be involved 
at all. Furthermore, 72% of the neurologists stated that their 
patients were fully involved in the decision process. This is 
high in comparison with most countries involved in the study 
by Riñon et al, where on average, 47% of the physicians 
stated such.7 Although most Dutch patients (86%) indi-
cated being involved in the decision-making process, 14% 
reported that their treatment was selected for them without 
any discussion of the options. In the study by Riñon et al, 
this situation occurred in 28% of the patients. The prefer-
ence of patients themselves not to be involved or the lack 
of treatment options in specific cases may have made this 
situation possible. In a previous study in the Netherlands in 
2006, a similar percentage of patients (15%) stated that the 
information had been insufficient to make a proper choice 
when choosing treatment.6 Based on these findings, there is 
still a need for improving patient involvement and patient–
physician communication.
Treatment choice
Patients considered both the effectiveness of the treatment 
for reducing relapses and the effectiveness of the treatment 
for reducing disease progression as the most important 
factors when deciding what treatment to take. Treatment 
frequency and possible side effects of the treatment were 
selected as third and fourth important factors, respectively. 
Although these factors are less often selected by patients as 
the most important factors in the choice of treatment, “how 
the treatment affects quality of life” and the “long-term 
safety profile” are rated highly important. In a recent study, 
patient preferences for injectable treatments in MS were 
gathered through a discrete-choice experiment, indicating 
trade-offs that people were willing to make.9 In that study, 
certain changes in injection frequency were as important to 
the MS patients as treatment efficacy. Although we did not 
conduct a choice experiment and the results cannot be easily 
compared, the MS patients in this study selected treatment 
efficacy as the most important factor when selecting a treat-
ment, beyond injection frequency. Considering treatment 
efficacy, we found that reducing the number of relapses and 
reducing disease progression were considered almost equally 
(highly) important by the MS patients in the current study.
The MS patients and MS-specialized neurologists in the 
Netherlands differed in their experience on treatment goals 
that are being discussed. Treatment goals such as the reduc-
tion in disease progression (indicated as a very important 
factor in the treatment choice by the MS patients), the reduc-
tion or prolongation of time to long-term disability, and the 
reduction in new magnetic resonance imaging lesions are 
much less often discussed with patients than indicated by 
the neurologists. It seems debatable whether patients would 
explicitly remember all these various treatment goals being 
discussed with them. Still, the fact that the most important 
factor in the treatment choice, ie reduction in disease pro-
gression, is discussed with only 69% of the patients, while 
94% of the neurologists indicate that this goal is a topic of 
discussion, is a finding of interest.
Adherence
Almost all neurologists (94%) in the current study felt that 
adherence is an issue when treating the MS patients. In 
contrast, in the study by Riñon et al, most physicians (59%) 
did not consider adherence as an issue when treating the MS 
patients. This is a remarkable difference, even more so when 
considering that adherence was operationalized in exactly the 
same manner in both studies.
The neurologists’ estimates concerning the percentage of 
patients taking a treatment break were very diverse, ranging 
from 5% to 80% of the patients. The neurologists estimated 
that on average, 16% discontinued treatment. In the cur-
rent study, 23% of the MS patients reported taking a break 
from treatment for 1 day and 19% reported once having 
discontinued treatment. In the study by Riñon et al, the per-
centage of patients taking a treatment break varied between 
countries from 16% to 47%.7 The scale of nonadherence in 
terms of treatment breaks was overestimated by more than 
half of the neurologists participating in this study. The fact 
that almost all of our neurologists consider adherence as 
an issue in treatment with DMDs may have resulted in this 
overestimation, which is in sharp contrast with the high levels 
of underestimation found by Riñon et al. Another option is 
that the number of treatment breaks was underreported by 
the MS patients in this study. Providing socially desirable 
answers is a general issue when using self-report measures. 
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The true level of treatment adherence can only be verified 
in studies using more objective measures. Both neurolo-
gists and patients need adequate up-to-date information on 
this topic.
The patients and neurologists both noted side effects and 
lack of efficacy as the most important reasons for nonadher-
ence. The neurologists mentioned injection-site reactions and 
flu-like symptoms as the two side effects with the greatest 
impact on treatment adherence, followed by mood changes. 
The patients named a diversity of treatment side effects as 
reasons to discontinue treatment. The association between 
adverse events, such as flu-like symptoms, injection-site 
reactions, and lipoatrophy, and long-term adherence has 
been previously described.6,10 While neurologists view 
either a combination of physical and psychological factors 
(33%), physical factors alone (33%), or psychological fac-
tors alone (33%) as most likely reasons for nonadherence, 
the majority of patients noted physical factors as the main 
reason for nonadherence. This may be related to a reluctance 
to acknowledge the involvement of psychological factors by 
patients, or perhaps, patients perceive these factors as less 
relevant to treatment adherence. Previous studies found that 
cognitive impairment, depression, and needle phobia may 
negatively affect treatment adherence.10 The use of periodic 
checks with a simple questionnaire in the waiting room 
may help neurologists become more aware of their patients’ 
treatment expectations and barriers.11 Neurologists, MS 
nurses, and informative websites are the most commonly 
named sources of information for managing treatment with 
DMDs. More than one-quarter of the patients would like to 
have more information about their treatment, either via the 
neurologist, MS nurse, websites with accurate information, 
brochures or a patient organization.
At the time this survey was sent, oral medication as a first 
line treatment became available in the Netherlands (October 
2014). One of the inclusion criteria was that patients had 
to be on injectable DMDs, and because of the recent intro-
duction of first-line oral treatment, lack of experience with 
these new oral DMDs, and the ability to compare our data 
with the results of the study of Riñon et al, we decided to 
stick to the earlier defined criteria. Out of several potential 
future treatment options, many patients indicated that oral 
treatment would benefit them most as they would not have 
to take injections anymore. However, the MS patients in this 
sample would still choose to take injectables if oral treatment 
was going to be less effective. In this respect, it should be 
kept in mind that all the MS patients in this study were cur-
rently using injectable DMDs. Preferences may be different 
in patients who are not taking or stopped taking injectables. 
Neurologists indicated seeing most benefit in new specific 
biological therapies. Interestingly, one-quarter of the neurolo-
gists provided as alternative a potential future treatment that 
would have an effect on disease progression.
limitations
Although this study provides new information on Dutch 
patient and neurologist perspectives on the use of DMDs, 
there are some limitations that were also mentioned in the 
study by Riñon et al.7 These are the unavoidable differences 
in the formulation of questions posed in the patient and 
neurologist surveys and the fact that the neurologists in this 
study were not necessarily the treating neurologists of the 
MS patients who participated in this study. Furthermore, 
the neurologists included in this study have treated many 
MS patients. There may be a larger discrepancy between 
patient–neurologist perspectives in neurologists with less 
clinical experience with the MS patients. Another limitation 
is the relatively low number of participating neurologists as 
compared to the relatively high number of participating MS 
patients. This is a direct result of our decision to invite only 
MS-specialized neurologists. In future studies, it would be 
interesting to also include general neurologists and aim at 
directly comparing the views of neurologists and the patients 
they treated. Finally, the results could not be specified in 
terms of disease characteristics (eg, disease duration, dura-
tion of DMD use, level of disability) as this information 
was not available. The diversity in patient experiences and 
perspectives may be related to diverse disease characteristics. 
However, a specification of perspectives in terms of disease 
characteristics was not the main focus of this study.
Furthermore, the field involved in the treatment of MS 
is rapidly changing and a comparable study should be done 
within a few years with the inclusion of the new available 
oral medications and the new injectables. This study may 
use a revealed or stated preference method to examine trade-
offs in treatment choices that people are willing to make.9 
Positive aspects are the representative number of included 
MS patients and Dutch neurologists specialized in MS. The 
questionnaire was adequately designed by Riñon et al7 and 
adapted in collaboration with the clinical experts.
Conclusion
We found some differences in the experiences and perspec-
tives of the participating MS patients and MS-specialized 
neurologists concerning information provision and adher-
ence to DMDs. Dutch MS neurologists are very supportive 
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of patient involvement and aim to discuss various treatment 
goals. The MS patients included in this study indicated that 
important treatment goals were not always discussed with 
them, and 14% reported that their treatment was selected for 
them without any discussion of the options. We found that the 
MS patients considered the effectiveness of the treatment for 
reducing relapses and the effectiveness of the treatment for 
reducing disease progression as the most important factors 
when deciding what treatment to take. As in the study 
by Riñon et al, we found evidence for suboptimal patient 
adherence to MS therapy, due to diverse side effects, lack 
of efficacy, or practical issues. As compared to these patient 
reports, the scale of suboptimal adherence was overestimated 
by more than half of the neurologists. In this respect, there 
may be a large focus on adherence in the Netherlands, but 
less access to adequate up-to-date information on this topic. 
Finally, it is important to stress that the neurologist is consid-
ered the most consulted source of information for treatment 
management by MS patients.
This information on patient and neurologist perspec-
tives may be very helpful for health care professionals and 
professionals in health care education. Education programs 
for both neurologists and patients11 may improve patient 
involvement and patient–physician communication. There is 
a need for up-to-date information about possible treatments 
and treatment management. Accurate websites, brochures, 
medication choice models, and independent expert summa-
ries of relevant scientific literature (indicated by neurologists) 
would be very helpful in this respect.
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